Saturday 26 September 2020 ,
Latest News
30 March, 2020 00:00 00 AM

ACE inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19

MedicalXpress
ACE inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19

James Diaz, MD, MHA, MPH & TM, Dr. PH, Professor and Head of Environmental Health Sciences at LSU Health New Orleans School of Public Health, has proposed a possible explanation for the severe lung complications being seen in some people diagnosed with COVID-19.

The SARS beta coronaviruses, SARS-CoV, which caused the SARS (Severe Acute Respiratory Syndrome) outbreak in 2003 and the new SARS-CoV-2, which causes COVID-19, bind to angiotensin converting enzyme 2 (ACE2) receptors in the lower respiratory tracts of infected patients to gain entry into the lungs. Viral pneumonia and potentially fatal respiratory failure may result in susceptible persons after 10-14 days.

"Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are highly recommended medications for patients with cardiovascular diseases including heart attacks, high blood pressure, diabetes and chronic kidney disease to name a few," notes Dr. Diaz. "Many of those who develop these diseases are older adults. They are prescribed these medications and take them every day."

Research in experimental models has shown an increase in the number of ACE2 receptors in the cardiopulmonary circulation after intravenous infusions of ACE inhibitors.

"Since patients treated with ACEIs and ARBS will have increased numbers of ACE2 receptors in their lungs for coronavirus S proteins to bind to, they may be at increased risk of severe disease outcomes due to SARS-CoV-2infections," explains Diaz.

Diaz writes, this hypothesis is supported by a recent descriptive analysis of 1,099 patients with laboratory-confirmed COVID-19 infections treated in China during the reporting period, December 11, 2019, to January 29, 2020. This study reported more severe disease outcomes in patients with hypertension, coronary artery disease, diabetes and chronic renal disease. All patients with the diagnoses noted met the recommended indications for treatment with ACEIs or ARBs. Diaz says that two mechanisms may protect children from COVID-19 infections—cross-protective antibodies from multiple upper respiratory tract infections caused by the common cold-causing alpha coronaviruses, and fewer ACE2 receptors in their lower respiratory tracts to attract the binding S proteins of the beta coronaviruses.

He recommends future case-control studies in patients with COVID-19 infections to further confirm chronic therapy with ACEIs or ARBs may raise the risk for severe outcomes.

In the meantime he cautions, "Patients treated with ACEIs and ARBs for cardiovascular diseases should not stop taking their medicine, but should avoid crowds, mass events, ocean cruises, prolonged air travel, and all persons with respiratory illnesses during the current COVID-19 outbreak in order to reduce their risks of infection."

Courtesy: Louisiana

State University

 

Comments

Most Viewed
E-Paper
More story
Editor Speaks

Editor Speaks

Tuberculosis is an age old disease and first spread probably 8000 years back. Killer T.B was described in India 3000 B.C. Mummified bodies of Egypt have…
World Tuberculosis Day 2020

World Tuberculosis Day 2020

Each year, we commemorate World Tuberculosis (TB) Day on March 24 to raise public awareness about the devastating health, social and economic consequences…
Tuberculosis (TB): Symptoms, causes & treatment

Tuberculosis (TB): Symptoms, causes & treatment

What is Tuberculosis? Tuberculosis -- or TB, as it’s commonly called -- is a contagious infection that usually attacks your lungs. It can spread…
WHO on Tuberculosis

WHO on Tuberculosis

Key facts •    A total of 1.5 million people died from TB in 2018 (including 251 000 people with HIV). Worldwide, TB is one of the…
Hearing loss screening for patients with TB and diabetes urged

Hearing loss screening for patients with TB and diabetes urged

MUHAMAMD ZAHIR HASSAN NABIL On this World Tuberculosis Day, Bangladesh remains one of 30 high TB and MDR-TB burden countries with 221 people affected…
Autism rates declining among wealthy whites, escalating among poor

Autism rates declining among wealthy whites, escalating among poor

Wealthy, white California counties—once considered the nation's hotbeds for autism spectrum disorder (ASD) - have seen prevalence flatten or…
What is Coronavirus (COVID-19)?

What is Coronavirus (COVID-19)?

COLLEEN DOHERTY, MD   The 2019 Novel Coronavirus (COVID-19) Outbreak COVID-19 is a new type of coronavirus, a common family of viruses, which surfaced…
Coronavirus patients, doctors seem to be temporarily losing their sense of taste and smell — here’s why

Coronavirus patients, doctors seem to be temporarily losing their sense of taste and smell — here’s why

ABBY HAGLAGE Healthcare workers wait for people to arrive at a COVID-19 mobile testing site in Florida. New reports from the UK show that both doctors…
10 common health conditions that may increase risk of death from the coronavirus, including diabetes and heart disease

10 common health conditions that may increase risk of death from the coronavirus, including diabetes and heart disease

According to a report on patient characteristics from Italy's National Institute of Health released on March 17, 99% of COVID-19 patients who have…
Coronavirus: Doctors urge conversations about dying

Coronavirus: Doctors urge conversations about dying

DR FAYE KIRKLAND Palliative care doctors are urging people to have a conversation about what they would want if they, or their loved ones, became seriously…
What does a self-quarantine look like?

What does a self-quarantine look like?

Many peoples are choosing -- or have been told -- to self-quarantine to slow the spread of COVID-19. Doctors at the University of Texas Health Science…
FDA approves Nurtec ODT (rimegepant) for the acute treatment of migraine in adults

FDA approves Nurtec ODT (rimegepant) for the acute treatment of migraine in adults

Biohaven Pharmaceutical Holding Company Ltd. recently announced that the U.S. Food and Drug Administration (FDA) has approved Nurtec ODT (rimegepant)…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting